Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Messina | OTHER |
| Universita di Verona | OTHER |
Not provided
Not provided
Not provided
Not provided
We hypothesize that the use of the Control-IQ system positively influences glycemic control in teenagers with type 1 diabetes during physical activity. To test this hypothesis, we will evaluate the glucose profiles (based on CGM metrics) of adolescents engaging in different types, intensities, and durations of physical activity over a 14-day period, in real-life conditions. We will compare glucose control on exercise days with that on sedentary days.
As a secondary objective, we will investigate the influence of factors such as anthropometric characteristics, type and duration of exercise, the use of the exercise mode and other management strategies used for physical activity, on glycemic outcomes.
Regarding the safety, we will report any episodes of severe hypoglycemia or diabetic ketoacidosis (DKA).
This is an observational, open-label, non-randomized, real-world study. Each participant will be provided with a diary to record detailed information about physical activity sessions over a 14-day period, including type, intensity, and duration of exercise, and timing and composition of pre-exercise meals. Clear instructions on how to complete the diary will be provided.
CGM metrics will be analyzed throughout the 14-day observation period, including time in range, time in tight range, time above range, time below range, mean glucose level, and coefficient of variation. A daily comparison will be performed between metrics recorded on days of physical activity and sedentary days, assessing the entire day as well as daytime (07:00-23:00) and nighttime (23:00-07:00) periods.
The influence of factors such as anthropometrics, type of physical activity, the use of the exercise mode and other specific management strategies, type and duration of exercise, and pre-exercise meals on CGM metrics will be evaluated.
The frequency of severe hypoglycemia and DKA episodes, as defined by international guidelines, will be assessed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tandem t:slim X2 with Control-IQ technology | Device | Control-IQ is one of the second-generation AID technologies currently available worldwide and is approved for people > 6 years. Control-IQ can predict glucose levels 30 minutes in advance and automatically adjust basal insulin delivery, providing corrective boluses if needed. The system can prevent hypoglycemia by suspending insulin delivery if glucose is predicted to drop below 70 mg/dl (8). Additionally, the device offers specific settings for circumstances such as sleep or exercise. When the exercise mode is activated, the system temporarily raises the minimum glucose target from 112.5 to 140 mg/dl to minimize the risk of hypoglycemia, a common effect of physical activity. |
| Measure | Description | Time Frame |
|---|---|---|
| Time in range (%) | Time spent with sensor glucose between 70 and 180 mg/dl (3.9 and 10 mmol/L) | 14 days |
| Time in tight range (%) | Time spent with sensor glucose between 70 and 140 mg/dl (3.9 and 7.8 mmol/L) | 14 days |
| Time above range level 1 (%) | Time spent with sensor glucose between 180 and 250 mg/dl (10.1 and 13.9 mmol/L) | 14 days |
| Time above range level 2 (%) | Time spent with sensor glucose > 250 mg/dl (13.9 mmol/L) | 14 days |
| Time below range level 1 (%) | Time spent with sensor glucose between 54 and 70 mg/dl (3.0 and 3.8 mmol/L) | 14 days |
| Time below range level 2 (%) | Time spent with sensor glucose < 54 mg/dl (3.0 mmol/L) | 14 days |
| Mean sensor glucose (mg/dl or mmol/L) | 14 days | |
| Coefficient of variation (%) | 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| Daytime (h 07.00-23.00) Time in Range (%) | 14 days | |
| Nighttime (h 23.00 - 07.00) Time in Range (%) | 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| Diabetic ketoacidosis episodes | (safety) | 14 days |
| Severe hypoglycemia episodes | (safety) | 14 days |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adolescents with type 1 diabetes, using Control-IQ technology, and engaging in regular physical activity
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bruno Bombaci, MD | Contact | +393473931038 | brunobombaci@gmail.com | |
| Giuseppina Salzano, PhD MD | Contact | gsalzano@unime.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital of Messina | Recruiting | Messina | Italy | 98125 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D001519 | Behavior |
Not provided
Not provided